breast cancer

Overview

Breast cancer is a heterogeneous Malignant Disease arising from breast tissue, most commonly from the epithelial cells of the ducts or lobules. It is one of the most frequently diagnosed cancers worldwide and remains a leading cause of cancer-related mortality among women, particularly because of metastatic disease, therapy resistance, and biologic diversity across subtypes. Clinically, breast cancer is often classified by hormone receptor status and other molecular features, which influence prognosis and treatment selection.

From a biomedical perspective, breast cancer is not a single entity but a spectrum of diseases shaped by tumor-intrinsic alterations and the surrounding tumor microenvironment. Recent research has emphasized pathways involving oestrogen receptor signaling, PI3K/Akt signaling, DNA damage repair, ferroptosis, cuproptosis, checkpoint inhibitor, and interactions with macrophage, dendritic cell, B-cell, and T-lymphocytes populations. These mechanisms are being explored to improve diagnosis, predict response, and overcome resistance to therapies such as paclitaxel, docetaxel, olaparib, radiation therapy, and Targeted Cancer Therapy.

Focus of Latest Publications

Recent publications describe breast cancer as a major clinical and research focus across diagnosis, prognosis, treatment resistance, supportive care, and precision oncology. Several studies centered on metastatic or hormone receptor-positive disease, including single-cell transcriptomics of HR-positive metastatic breast cancer to better define its immunological landscape, and analyses of tertiary lymphoid structures as potentially favorable immune features associated with improved prognosis and immunotherapy response. Another study examined early local immune activation after intra-operative radiotherapy in human breast tissue, reflecting ongoing interest in how radiation therapy reshapes the immune microenvironment.

A substantial portion of the recent literature focused on imaging and prediction of treatment response. Dynamic contrast-enhanced MRI and 18F-FDG PET/CT were compared for their ability to predict pathological response after neoadjuvant therapy, while other studies used deep learning, machine learning, and radiopathomic graph models to predict recurrence, adjuvant radiation benefit, and pathologic complete response. Digital breast tomosynthesis was also used in an advanced deep learning framework for breast cancer detection. These studies collectively reflect a shift toward multimodal prediction using imaging, pathology, and longitudinal data.

Therapy resistance was another major theme. One study investigated PCK1 as a target to overcome Cdk4/6 inhibitor resistance, while another reported that CTDSPL2 facilitates resistance to paclitaxel by suppressing SCYL1 phosphorylation. Additional work examined hypoxia-induced exosomal CAMTA1 in radio-resistance, UBD in malignant progression, and antibody-drug conjugate resistance. These findings align with broader efforts to identify biomarkers and vulnerabilities linked to drug efflux pumps, genomic stability, and tumor stemness.

Several studies explored novel therapeutic strategies and delivery systems. Nanoparticle-based approaches were used for photothermal therapy, sonodynamic immunotherapy, and targeted drug delivery, including copper-based nanoplatforms designed to enhance cuproptosis and anti-metastatic immunity, and magnetic nanoplatforms intended for breast cancer applications. Other work evaluated co-delivery systems for chemoprevention, bio-magnetic nanomedicine, and AI-assisted delivery systems. In parallel, in silico studies screened natural compounds and phytochemicals, including garlic-derived organosulfur compounds, royal jelly bioactives, Hydnocarpus wightianus phytochemicals, and Poikilospermum suaveolens root fractions, against breast cancer biomarkers or signaling pathways.

Immunology and tumor microenvironment research also featured prominently. Studies examined immune-related biomarkers such as CD2, CD3D, CXCL9, CXCL13, CCL5, CD74, SELE, GSTM5, and NY-ESO-1, as well as the roles of macrophage polarization, anti-PD-L1 strategies, TIGIT-related immune regulation, and cGAS-STING activation. CAR T cell therapies and CAR-NK approaches were also referenced in the broader research context, reflecting interest in engineered cellular immunotherapy for solid tumors including breast cancer. Related work on ferroptosis, glutathione, reactive oxygen species, and mitochondrion-associated stress responses further underscores the importance of metabolic and redox regulation in breast cancer biology.

Prevention, survivorship, and supportive care were also represented. One study assessed adherence to an exercise intervention during (neo-)adjuvant chemotherapy, while another developed and validated a spiritual care e-book for Chinese women undergoing chemotherapy. A protocol for a systematic review addressed body-oriented interventions for survivors, and another paper described long-term survivors’ experiences and needs, including persistent physical and cognitive effects of treatment. Risk-related research included the association between FTO genotype and breast cancer risk after bariatric surgery, and a feasibility trial protocol for intermittent diet to prevent weight gain in women at increased risk of breast cancer.

Surgical and radiotherapy-related innovation remained important. Precision delineation of surgical margins was studied using a KIAA1363-targeted near-infrared fluorescent probe, and a phase 2 trial evaluated single-fraction high-gradient adjuvant partial breast irradiation in early-stage, hormone-positive breast cancer. Another prospective trial examined hypofractionated stereotactic radiation therapy for brain metastases from breast cancer. Together, these studies show continued efforts to refine local control while reducing toxicity.

Key Publications

May Comparative Assessment of Free Energy Computational Methods for Revealing the Interactions Driving PARP1 Selective Inhibition. (Journal of chemical information and modeling, 2026, PMID 41999312): "...used in ovarian, breast, and prostate tumors, among others."
May Development and content validation of spiritual care e-book for Chinese breast cancer women undergoing chemotherapy. (Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer, 2026, PMID 42081034): "This study aimed to develop and validate a spiritual care e-book for women with breast cancer undergoing chemotherapy."
May Comparison of changes in dynamic contrast-enhanced magnetic resonance imaging and flourine-18 fluorodeoxyglucose positron emission tomography/computed tomography parameters from baseline to post-neoadjuvant therapy in predicting pathological response in breast cancer. (Diagnostic and interventional radiology (Ankara, Turkey), 2026, PMID 40824136): "This study aimed to compare the value of differences (Δ) in parameters obtained via both dynamic contrast-enhanced (DCE) magnetic resonance imaging (MRI) and flourine-18 fluorodeoxyglucose positron emission tomography/computed tomography (18F-FDG PET/CT) between baseline and post-neoadjuvant therapy in predicting the pathological response to neoadjuvant therapy in breast cancer."
May What is the adherence to an exercise intervention during (neo-)adjuvant chemotherapy among Swedish patients with breast cancer? Data from the Phys-Can randomised controlled trial. (BMJ open, 2026, PMID 42097659): "While exercise adherence is known to vary during cancer treatment, little is known about what predicts these changes during chemotherapy or within individual treatment cycles for breast cancer."
May Deciphering the immunological landscape of HR + metastatic breast cancer: insights from single-cell transcriptomics. (Human cell, 2026, PMID 42101520): "Breast cancer remains the leading cause of cancer-related mortality among women worldwide, primarily due to metastatic complications."
May Node properties of biomarkers within the protein-protein interaction network derived from breast cancer-associated genes. (PloS one, 2026, PMID 42090378): "Analyzing the network properties of cancer biomarkers within protein-protein interaction (PPI) networks is valuable for discovering novel biomarker candidates."
May In silico evaluation of garlic-derived organosulfur compounds as multi-target inhibitors of breast cancer biomarkers. (PloS one, 2026, PMID 42090396): "Breast cancer is the leading cause of cancer mortality among women globally, and drug resistance complicates treatment."
May Theranostic CuS/ALA Nanoprobes Modulate Drug Efflux Pumps and Synergize the Photoacoustics-Guided Photothermal Breast Cancer Therapy. (ACS applied materials & interfaces, 2026, PMID 42013020): "Breast cancer remains a clinical hurdle despite technoclinical advancements, primarily due to drug resistance mechanisms, from overexpression of drug efflux pumps."
May Association between FTO rs9939609 genotype and breast cancer risk after bariatric surgery in the Swedish Obese Subjects study. (Scientific reports, 2026, PMID 42091990): "Weight loss by bariatric surgery lowers breast cancer risk, particularly in women with baseline hyperinsulinemia, but it is unclear whether this effect varies by FTO genotype."
May The Effects of Body-Oriented Interventions on Cancer-Related Symptoms of Women Who Survived Breast Cancer: Protocol for a Systematic Review. (JMIR research protocols, 2026, PMID 42066295): "Breast cancer is one of the most prevalent cancers worldwide, with a 5-year survival rate exceeding 90%."

Show 53 more publications

May MuTriM: A multiscale deep learning model integrating longitudinal radiomics and pathomic features for predicting recurrence and adjuvant radiation benefit in breast cancer. (European journal of cancer (Oxford, England : 1990), 2026, PMID 41850009): "We present MuTriM, a multimodal deep learning model integrating DCE-MRI and whole-slide pathology to predict survival and radiation benefit in breast cancer."
May Integrative computational and experimental approaches to Hydnocarpus wightianus phytochemicals: Targeting breast Cancer through systems biology, molecular dynamics simulations, and in vitro validation in MDA-MB-231 cells. (Bioorganic chemistry, 2026, PMID 41666623): "Breast cancer causes a huge burden on healthcare systems, and it is crucial to identify new drugs from nature sources with better efficacy and safety profile."
May Targeting PCK1 to overcome CDK4/6 inhibitor resistance for breast cancer therapy. (Cancer letters, 2026, PMID 41748011): "We found that these drugs, in combination with CDK4/6 inhibitors, exhibit a synergistic effect in suppressing breast cancer."
May Preparation of styrene-maleic anhydride copolymer nanobrush chromatographic stationary phase and its application in phospholipid analysis of exosomes. (Analytica chimica acta, 2026, PMID 41796493): "Phospholipids in serum exosomes are promising biomarkers for breast cancer diagnosis."
May Hypoxia‑induced exosomal CAMTA1 promotes radio‑resistance in MDA‑MB‑231 cells by regulating NRG1 to mediate M2 macrophage polarization. (International journal of oncology, 2026, PMID 41891984): "Radiotherapy remains an irreplaceable treatment modality for breast cancer (BC)."
May Radiopathomic Graph Deep Learning for Multiscale Spatial-Contextual Modeling of Intratumoral Heterogeneity to Predict Breast Cancer Response to Neoadjuvant Therapy. (Radiology. Artificial intelligence, 2026, PMID 41949455): "...to predict pathologic complete response (pCR) to neoadjuvant therapy in breast cancer."
May Proximity Mapping of the ER Proteome Reveals Metastasis-specific Candidate Biomarkers in Breast Cancer Cell Lines. (Cancer genomics & proteomics, 2026, PMID 42055627): "Breast cancer is the most frequently diagnosed cancer among women."
May Gossypol Inhibits GLI3-dependent SHH Signaling to Selectively Target SPOP-deficient Breast Cancer Cells. (Anticancer research, 2026, PMID 42049345): "Breast cancer remains one of the leading causes of cancer-related mortality among women."
May Usability of a Reminder App that May Help to Reduce Radiotherapy-related Skin Toxicity in Patients With Breast Cancer. (In vivo (Athens, Greece), 2026, PMID 42049411): "Patients irradiated for breast cancer may experience acute skin toxicity."
May Breast Cancer Recurrence After 46 Years of Remission: A Case Report and Clinical Implications. (In vivo (Athens, Greece), 2026, PMID 42049437): "Breast cancer is the most commonly diagnosed malignancy among women worldwide."
May Exploration of CD2 and CD3D as potential immune-related biomarkers for IORT in breast cancer treatment. (Medicine, 2026, PMID 42065189): "Breast cancer is a prevalent malignancy among women worldwide."
May Engineering NK and T cells with metabolite-sensing receptors to target solid tumors. (Nature immunology, 2026, PMID 41872506): "In vivo and in vitro CRISPR activation screens using NK-92 cells identified GPR183, GPR84, GPR34 and GPR18 as top enhancers of infiltration and chemotaxis to breast and ovarian cancers."
May Multi-ancestry genome-wide association and integrated multi-omics analyses of endometriosis and its clinical manifestations. (Nature genetics, 2026, PMID 42056605): "...highlighted potential treatments currently used for breast cancer, contraception and preterm birth prevention."
May Metabolic enzymes and immune receptors as emerging checkpoints in breast cancer: mechanisms, clinical trials, and therapeutic implications. (Naunyn-Schmiedeberg's archives of pharmacology, 2026, PMID 42059928): "Breast cancer remains the most frequently diagnosed malignancy among women worldwide and continues to pose significant challenges due to its heterogeneity and complex interactions with the immune system."
May Prevent 6:1 trial: pI rotocol for a feasibility trial of a 6:1 intermittent diet for weight gain prevention in women at increased risk of breast cancer. (BMJ open, 2026, PMID 42055614): "Weight gain in adulthood is a common potentially modifiable breast cancer risk factor."
May Targeting p38α, p38γ, and ERα with bioactive compounds from royal jelly for anti-breast cancer activity: A comprehensive in-silico study using fingerprint analysis, molecular dynamics, MEP, and PCA. (Biochemical and biophysical research communications, 2026, PMID 41819753): "Studying receptors that play critical roles in breast cancer continues to present various challenges."
Apr Multigated DNA Cascade Amplifier for Ultrasensitive Spatiotemporal Imaging of PLS3 mRNA at the Single-Cell Level for Early Detection of Breast Cancer Metastasis. (Analytical chemistry, 2026, PMID 41961955): "Early detection of small metastatic foci is crucial for improving breast cancer patient survival."
Apr In Vitro Evaluation of PARP1 Inhibitor Olaparib-Cyanine Dye Conjugate for the Treatment of Glioblastoma. (ChemMedChem, 2026, PMID 42035252): "Inhibition of DNA damage repair is a common mechanism to induce cancer cell death and, therefore, to treat cancers such as breast, prostate and ovarian cancer."
Apr Design, Synthesis, and Biological Evaluation of Novel Triazine-Based Dual Histone Deacetylase/phosphatidylinositol 3-kinase Inhibitors for Breast Cancer Therapy. (ChemMedChem, 2026, PMID 42035271): "Breast cancer is the most frequently diagnosed malignancy and a leading cause of cancer-related mortality among women worldwide."
Apr Exploration of the mechanism by which Ubiquitin-like protein UBD promotes malignant progression of breast cancer. (Medical oncology (Northwood, London, England), 2026, PMID 42043695): "Analysis of clinical specimens showed that UBD expression was significantly higher in primary breast cancer tissues than in normal breast tissues and was closely associated with key clinicopathological features in affected patients."
Apr CTDSPL2 facilitates resistance to paclitaxel in breast cancer cells by suppressing SCYL1 phosphorylation. (Cell cycle (Georgetown, Tex.), 2026, PMID 42041204): "Breast cancer (BC) exhibits significant heterogeneity and complexity and is leading causes of mortality in women globally."
Apr Long-term breast cancer survivors: experiences, needs, and proposals for person-centred care. (Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer, 2026, PMID 42034795): "Long-term breast cancer survivors experience permanent effects of cancer treatment such as reduced strength, aerobic capacity, and mobility, as well as cognitive, cardiac, or neurotoxic complications."
Apr Advanced deep learning framework for breast cancer detection using digital breast tomosynthesis images. (Biomedizinische Technik. Biomedical engineering, 2026, PMID 41521204): "Early and accurate detection of breast cancer is critical for improving patient survival outcomes."
Apr Precision Delineation of Surgical Margins across Breast Cancer Subtypes with a Novel KIAA1363-Targeted NIR Fluorescent Probe. (ACS sensors, 2026, PMID 41824291): "Surgical resection remains the first-line treatment for breast cancer, underscoring the need for precision tools for intraoperative margin delineation."
Apr Ablation, Osteoplasty, Reinforcement, and Internal Fixation Allows for Subsequent Hip Arthroplasty Reconstruction. (JBJS case connector, 2026, PMID 42030419): "A 34-year-old woman with stage IV breast cancer presented with bilateral acetabular metastases, a right pathological femoral fracture, and a left subtrochanteric impending fracture."
Apr Anticancer mechanisms of Poikilospermum suaveolens root fraction: ethnopharmacological relevance, signaling pathways, and in vitro/in silico studies on MCF-7 cells. (Journal of ethnopharmacology, 2026, PMID 41548615): "However, scientific evidence elucidating its molecular mechanisms against breast cancer remains limited."
Apr Co-delivery of fenretinide and perillyl alcohol for breast cancer pharmacological prevention through nanostructured lipid carriers: characterization, cellular studies and in vivo localization. (International journal of pharmaceutics, 2026, PMID 41864447): "Strategies available for breast cancer chemoprevention are of limited use, partially due to adverse effects."
Apr Co-encapsulated fluorescent magnetic nanoparticles for potential applications in breast cancer therapy: Exploratory in vitro and in vivo studies. (International journal of pharmaceutics, 2026, PMID 41895480): "Overall, these findings suggest that the developed magnetic nanoplatforms represents a promising candidate for breast cancer applications and merits further in vivo investigation to elucidate the action mechanism of encapsulated therapeutics and their pharmacologic activity."
Apr Role of ferroptosis on immunotherapy in breast cancer. (Molecular biology reports, 2026, PMID 42029800): "Breast cancer is the most prevalent cancer among women globally, and its rising incidence and mortality rates underscore the urgent need for new treatment strategies."
Apr Therapeutic potential of tertiary lymphoid structures in breast cancer (Review). (Molecular medicine reports, 2026, PMID 42028730): "Tertiary lymphoid structures (TLS) are organized immune aggregates within the tumor microenvironment that are associated with improved prognosis and immunotherapy response in breast cancer, yet their functional duality and therapeutic potential require further clarification."
Apr Use of AI to Predict and Support Medication Adherence in Patients With Breast Cancer: Systematic Review. (JMIR cancer, 2026, PMID 42013303): "Oral medications are commonly used in the treatment of breast cancer (BC), despite high rates of nonadherence."
Apr Game of clones: decipher lineage plasticity in hormone-driven cancers. (Cellular and molecular life sciences : CMLS, 2026, PMID 42014520): "...with emphasis on prostate and breast malignancies."
Apr Correction: MnO2-based nanoparticles remodeling tumor micro-environment to augment sonodynamic immunotherapy against breast cancer. (Biomaterials science, 2026, PMID 41811071): "Correction for 'MnO2-based nanoparticles remodeling tumor micro-environment to augment sonodynamic immunotherapy against breast cancer' by Haiqin Liao et al."
Apr Bio-magnetic nanomedicine for targeted drug delivery of breast cancer: green synthesis, functional design, and translational challenges. (Breast cancer research : BCR, 2026, PMID 42002783): "Breast cancer is an increasing cause of morbidity and death globally."
Apr Bioengineered iPSC-derived human macrophages with increased angiotensin-converting enzyme (ACE) expression suppress solid tumor growth. (Signal transduction and targeted therapy, 2026, PMID 41968179): "In vivo, studies using tumor xenografts for melanoma, breast cancer, and head and neck squamous cell carcinoma (HNSCC) showed a highly significant 3.4- to 7.2-fold reduction in solid tumor size following ACE-expressing ACE-iMac immunotherapy as compared to results with iMac."
Apr A robust RNAi nanoplatform for precise activation of cGAS-STING pathway and effective immune checkpoint blockade to potentiate cancer immunotherapy. (Journal of controlled release : official journal of the Controlled Release Society, 2026, PMID 41655906): "We herein developed a new and robust immunostimulatory RNA interfering (RNAi) nanoplatform to potentiate breast cancer (BCa) immunotherapy through precise activation of cGAS-STING pathway and effective immune checkpoint blockade."
Apr Augmenting cuproptosis and anti-metastatic immunity in breast cancer by copper-based nanoplatform for synergistic immunotherapy via lactate metabolic reprogramming and hypoxia alleviation. (Journal of controlled release : official journal of the Controlled Release Society, 2026, PMID 41679436): "Breast cancer remains a leading cause of cancer-related mortality in women, with the clinical efficacy of immune-checkpoint inhibitors limited by low tumor immunogenicity."
Apr Early local immune activation following intra-operative radiotherapy in human breast tissue. (Oncoimmunology, 2026, PMID 41943280): "Here, we present real-world immunoprofiling data from breast cancer patients undergoing breast-conserving surgery with (n=20) or without (n=29) intraoperative radiotherapy (IORT)."
Apr IDH enzyme inhibition in cancer therapy: mechanisms, mutational insights, and effects of IDH inhibitors in glioma, acute myeloid leukemia and chondrosarcoma. (3 Biotech, 2026, PMID 41821663): "as reported in various cancers, including lung and breast cancer."
Apr Discovery of novel circular RNAs of the apoptosis-related BAX gene in breast cancer, by combining nanopore and next-generation sequencing. (Molecular genetics and genomics : MGG, 2026, PMID 41843205): "However, the characterization and the regulatory potential of circRNAs deriving from key apoptotic genes remain poorly understood in breast cancer."
Apr Unraveling small non-coding RNAs with a significant post-transcriptional impact on breast cancer cell signaling, using a combinational sequencing approach. (Functional & integrative genomics, 2026, PMID 41866548): "Breast cancer (BrCa) is a predominant type of cancer with high mortality rates."
Apr Understanding and Overcoming Antibody-Drug Conjugate Resistance: Biological Mechanisms and Emerging Analytical Frameworks in Breast Cancer. (Advanced science (Weinheim, Baden-Wurttemberg, Germany), 2026, PMID 41874465): "Antibody-drug conjugates (ADCs) have revolutionized the treatment landscape of breast cancer by combining the precision of monoclonal antibodies with the potency of cytotoxic agents."
Apr Artificial intelligence and multi-omics convergence in breast cancer: Revolutionizing diagnosis, prognostication, and precision oncology. (Critical reviews in oncology/hematology, 2026, PMID 41616992): "Breast cancer (BC) is a highly heterogeneous malignancy and remains a major cause of cancer-related mortality among women worldwide."
Apr SELE is associated with reduced breast cancer susceptibility: Evidence from Mendelian randomization and single-cell transcriptome. (Translational oncology, 2026, PMID 41722201): "The role of circulating proteins in breast cancer (BC) early diagnosis remains unclear."
Apr An integrative multi-omics analysis leveraging Mendelian randomization and subsequent experimental validation prioritizes glutathione S-transferase mu 5 (GSTM5) as a genomic stability-related gene and a therapeutic vulnerability to PLK1 inhibition in breast cancer. (International journal of biological macromolecules, 2026, PMID 41794244): "Circadian rhythm disruption has been associated with increased breast cancer risk, yet the underlying molecular drivers remain unclear."
Apr Integrative immunogenomic and experimental characterization reveals CXCL9, CXCL13, CCL5 and CD74 as key oncogenic drivers in breast cancer. (Mammalian genome : official journal of the International Mammalian Genome Society, 2026, PMID 41920337): "Breast cancer remains the most prevalent malignancy among women worldwide, driven by complex interactions between tumor-intrinsic factors and the immune microenvironment."
Apr Integrating Multi-Omics and Artificial Intelligence for Personalized Breast Cancer Management: A Guide to Clinicians. (Cancer letters, 2026, PMID 41936855): "Breast cancer's (BC) diverse nature and global impact demand tailored clinical strategies."
Apr NY-ESO-1 in Triple-Negative Breast Cancer: Systematic Review, Meta-Analysis, and Immunotherapeutic Implications. (International immunopharmacology, 2026, PMID 41846058): "Breast cancer remains one of the most common types of cancer, including the subtype triple-negative breast cancer (TNBC) which is challenging to treat due to its aggressiveness."
Apr HMGB3: A pivotal orchestrator of therapy resistance and cancer stemness in human malignancies (Review). (Oncology reports, 2026, PMID 41930588): "Its aberrant upregulation has been revealed in numerous human malignancies, such as leukemia, as well as breast, bladder, colorectal and gastric cancer, and its expression levels have been established to be closely associated with poor prognosis of specific patients."
Apr The MCM/Lys-Cys nanodevices for the efficient gene delivery: An approach towardsMCP1gene manipulation using CRISPR technology. (Colloids and surfaces. B, Biointerfaces, 2026, PMID 41443126): "Breast cancer continues to be the most common malignancy among women worldwide, requiring novel therapeutic approaches."
Apr Nanotechnology based targeted drug delivery systems for breast cancer: challenges, recent advancement and future perspectives. (Nanomedicine (London, England), 2026, PMID 41773625): "Globally, breast cancer remains a leading causes of cancer-related mortality among women, emphasizing the need for more effective therapies."
Apr Long-Term Results of a Phase 2 Prospective Clinical Trial of Single-Fraction, High-Gradient Adjuvant Partial Breast Irradiation in Early-Stage, Hormone-Positive Breast Cancer. (International journal of radiation oncology, biology, physics, 2026, PMID 40912507): "This study evaluates the long-term outcomes of single-fraction, high-gradient partial breast irradiation (BreaStBRT) as a postoperative treatment in patients with early-stage, hormone-positive breast cancer."
Apr A Prospective Phase 2 Trial of Hypofractionated Stereotactic Radiation Therapy for Patients With 1 to 10 Brain Metastases From Breast Cancer. (International journal of radiation oncology, biology, physics, 2026, PMID 41453455): "Although fractionated stereotactic radiation therapy (FSRT) remains understudied for the management of breast cancer brain metastases, this study aimed to investigate its therapeutic efficacy and safety in the context of contemporary systemic therapies."